For patients facing cancers with limited treatment options, a groundbreaking radiotherapy technology is poised to become available‌ in France, offering a potential “second chance” at remission. Boron Neutron Capture Therapy (BNCT), an advanced and highly targeted form of radiation, ​is ‌the focus of a new initiative called AMBRE (Alliance Montpellier-Méditerranée pour la BNCT et l’Excellence⁣ en Radiothérapie).

The AMBRE project, launched in late December 2023 through⁢ a collaboration between the ⁢Montpellier cancer Institute (ICM) and American company TAE Life⁤ Sciences, aims to establish BNCT as a viable ⁣treatment option within the ‍French healthcare ⁤system. Professor David Azria, head of​ the Oncology ‌Radiotherapy department at ⁤ICM‌ and‍ president of the french Society of Oncological Radiotherapy, has expressed strong anticipation for the program’s potential.

BNCT differs from conventional radiotherapy by ‍specifically targeting cancer cells.​ The process involves administering a boron-containing drug that selectively accumulates within tumor tissue. Following this, a beam of low-energy ⁣neutrons is directed at the​ tumor. When the neutrons ⁤interact with the boron, a nuclear reaction occurs, delivering a highly ⁢localized and potent dose of radiation directly to the cancer cells, minimizing damage to ⁣surrounding healthy tissue.

This targeted approach makes BNCT notably promising for cancers that are difficult to treat with traditional methods, or those that have recurred ‍after initial treatment. Professor ‍Azria specifically highlighted the potential benefits ​for patients with aggressive brain tumors like glioblastoma, pancreatic cancer, and cancers of the ⁤ear, nose, and throat (ENT cancers). The therapy is envisioned‍ as a crucial option for cancers that have already been treated with conventional‍ radiotherapy but have sadly returned.

While still‍ a relatively new technology, BNCT has demonstrated ​encouraging results ‌in clinical trials and offers a beacon⁤ of hope for ⁤individuals facing challenging diagnoses. The establishment of BNCT capabilities‌ in France through the ⁤AMBRE project represents a significant ⁤step forward ⁢in the fight against ​cancer and underscores ‌the ongoing commitment to developing ⁣innovative and effective ⁢treatment strategies.